Iovance Biotherapeutics's ROE % for the quarter that ended in Mar. 2026 was -44.52%. Iovance Biotherapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 2.13.
Iovance Biotherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -20.90%.
Iovance Biotherapeutics ROE % Adjusted to Book Value Related Terms
Iovance Biotherapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Iovance Biotherapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iovance Biotherapeutics ROE % Adjusted to Book Value Chart
IOVA vs HRMY, NRIX, ZYME: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Iovance Biotherapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -20.90% mean?
Iovance Biotherapeutics (IOVA) has a ROE % Adjusted to Book Value of -20.90% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Iovance Biotherapeutics and its competitors.
Is Iovance Biotherapeutics' ROE % Adjusted to Book Value too high?
Iovance Biotherapeutics' current ROE % Adjusted to Book Value is -20.90%. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' ROE % Adjusted to Book Value compare to HRMY and NRIX?
Iovance Biotherapeutics' ROE % Adjusted to Book Value of -20.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current ROE % Adjusted to Book Value is -20.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Possible Value Trap. The stock's GF Value™ is $18.84, compared to a current price of $4.24 — trading 77.5% below its estimated fair value. The current ROE % Adjusted to Book Value is -20.90%. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current ROE % Adjusted to Book Value is -20.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued.
The current stock price of $4.24 is trading 77.5% below its estimated GF Value™ of $18.84.
GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.
Key valuation signals for IOVA:
ROE % Adjusted to Book Value: -20.90%
GF Value™: $18.84 vs. price of $4.24 (77.5% below fair value)
No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score
Get the complete analysis for IOVA
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOVA has been successfully added to your 
